SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies ​in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging ‌criticism that Novo's studies had design flaws. Although the trials failed to show statistically significant slowing of cognitive decline in patients given the drug,‌ "we still think it was the right decision.

"Our study provides a new direction to understand the whole evolutionary history of massive stars toward the formation of black hole binaries."

Picking the best pizza beating blend is a superb yet testing task for pizza sweethearts. Whether you favor exemplary flavors or more brave blends, the right blend of garnishes can el